Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q3 net loss narrows to $128 million; revenue falls to $9 million

Mixed Impact 3 of 5 earnings

Arcus Biosciences reported third-quarter 2026 results on November 4, 2026. Quarterly revenue fell to $9 million from $26 million, while the net loss narrowed to $128 million from $135 million, and the company said cash runway extends into 2029 after an October equity financing.

Key points

  • Q3 2026 net loss was $128 million, or $1.00 per share, versus $135 million, or $1.27 per share, in Q3 2025.
  • Q3 2026 revenue was $9 million versus $26 million a year earlier; the company expects full-year 2026 GAAP revenue of $70 million to $75 million.
  • Cash, cash equivalents and marketable securities were $694 million at September 30, 2026, plus $288 million gross proceeds from an October equity financing.
  • Enrollment in the PEAK-1 Phase 3 study is expected to complete in the next two to three months; PEAK-20 is expected to begin in the fourth quarter of 2026.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:08 PM ET
Accession number0001724521-26-000056

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.